Abbott Adds IgM Test To COVID-19 Diagnostic Line-Up
Executive Summary
The FDA has granted an emergency use authorization for a COVID-19 IgM antibody blood test that runs on Abbott’s Architect and Alinity platforms.
You may also be interested in...
Abbott’s 3Q $8.9Bn Sales Beat Wall Street Consensus, Medtech Sales Up 3.4%
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
FDA Grants EUA For Access Bio’s Lateral Flow COVID-19 Antigen Test
Access Bio joins Abbott as the second company with FDA authorization to distribute PCR, antigen and antibody tests for COVID-19.
Minute Insight: Abbott Plans Move Into Famous Chicago Skyscraper
Local newspapers in Chicago confirm that Abbott is leasing space in Chicago’s most famous building in an attempt to better serve employees who live closer to the city than its Lake County, IL, campus.